Kovid-19 vaccine manufacturers Pfizer Inc. and BioNtech SE said on Friday that they plan to file for an Emergency Use Authority that could allow their Kovid-19 vaccine to be used in the US next month.
For an epidemic-affected world, the US drugmaker and its German partner confirmed earlier this week that a final analysis of clinical trial data showed the shot was 95% effective in preventing the disease.
The companies said in a statement that filing with the Food and Drug Administration could allow the vaccine to be administered in the US in high-risk populations by the end of December.
In their application, Pfizer Inc. and Bayonet Tech SE have also included safety data on approximately 100 children between the ages of 12–15. The company stated that 45% of US trial participants are 56–85 years old.
Pfizer’s Chief Executive Officer Albert Borla has said the drug makers’ move marks an important milestone.
“Filling in the US represents an important milestone in our journey to deliver the Kovid-19 vaccine to the world and we now have a more complete picture of both efficacy and safety profiles,” Borla said in a statement.
STAY TUNED WITH US FOR MORE INTERESTING CONTENT ONLY ON DESINEW.XYZ